CStone Pharmaceuticals
Mengxin Chen is a Senior Medical Writer at CStone Pharmaceuticals since September 2018, with previous experience as a Medical Writer at Pfizer from July 2016 to September 2018 and in Regulatory CMC at Novartis from June 2015 to July 2016. Prior to these roles, Mengxin worked as a Scientist at WuXi AppTec from March 2012 to March 2015, focusing on designing and authoring stability protocols. Mengxin holds a Master's degree in Pharmaceutical Analysis and Quality Control from King's College London and Bachelor's degrees in Herbal Science from London Metropolitan University and Pharmaceutical Sciences from Shanghai University of Traditional Chinese Medicine.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.